Related references
Note: Only part of the references are listed.Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
Sabine Kahl et al.
DIABETES CARE (2020)
Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes
Lars Johansson et al.
DIABETES OBESITY & METABOLISM (2020)
Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease
Fabio Nascimbeni et al.
JOURNAL OF HEPATOLOGY (2020)
Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial
Eugene Han et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Effect of weight change and lifestyle modifications on the development or remission of nonalcoholic fatty liver disease: sex-specific analysis
Naoki Yoshioka et al.
SCIENTIFIC REPORTS (2020)
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
Mark L. Hartman et al.
DIABETES CARE (2020)
Incretin combination therapy for the treatment of non-alcoholic steatohepatitis
Aimo Kannt et al.
DIABETES OBESITY & METABOLISM (2020)
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
David M. Williams et al.
DIABETES THERAPY (2020)
Drug Therapy in Obesity: A Review of Current and Emerging Treatments
David M. Williams et al.
DIABETES THERAPY (2020)
Role of Extracellular Vesicles in the Pathophysiology, Diagnosis and Tracking of Non-Alcoholic Fatty Liver Disease
Lauren A. Newman et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis
Michelle L. Boland et al.
NATURE METABOLISM (2020)
Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study)
Anna Ozaki et al.
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS (2020)
Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial)
Yoshio Sumida et al.
HEPATOLOGY RESEARCH (2019)
The efficacy of saxagliptin in T2DM patients with non-alccholic fatty liver disease: preliminary data
Juan-Juan Li et al.
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA (2019)
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
Zobair M. Younossi et al.
JOURNAL OF HEPATOLOGY (2019)
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice
Amar Ali et al.
DIABETES THERAPY (2019)
Clinical Use of DPP-4 Inhibitors
Baptist Gallwitz
FRONTIERS IN ENDOCRINOLOGY (2019)
SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
Naser Eddin Gharaibeh et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2019)
Neurobehavioral dysfunction in non-alcoholic steatohepatitis is associated with hyperammonemia, gut dysbiosis, and metabolic and functional brain regional deficits
Sara G. Higarza et al.
PLOS ONE (2019)
Dual GIP-GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
Marie Bastin et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis
Yung Lee et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis
Tannous K. Fakhry et al.
SURGERY FOR OBESITY AND RELATED DISEASES (2019)
Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease
Mitsuko Inoue et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review
Henith Raj et al.
WORLD JOURNAL OF DIABETES (2019)
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
Mohammad Shafi Kuchay et al.
DIABETES CARE (2018)
Incretin hormones: Their role in health and disease
Michael A. Nauck et al.
DIABETES OBESITY & METABOLISM (2018)
Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future
Ana Ruth Araujo et al.
LIVER INTERNATIONAL (2018)
Glucagon-like peptide 1 in health and disease
Andreas Andersen et al.
NATURE REVIEWS ENDOCRINOLOGY (2018)
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease
Mario Masarone et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2018)
Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition
Debapriya Basu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOMEA (R) trial
Naveed Sattar et al.
DIABETOLOGIA (2018)
Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease
Teruki Miyake et al.
OPEN MEDICINE (2018)
Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis
Brian N. Finck
DIABETES (2018)
Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
Marta Seghieri et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis
Yuya Seko et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2018)
Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial
Shahinul Alam et al.
HEPATIC MEDICINE-EVIDENCE AND RESEARCH (2018)
Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study
Toshio Itani et al.
OBESITY SCIENCE & PRACTICE (2018)
Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study
Takashi Shibuya et al.
DIABETES OBESITY & METABOLISM (2018)
An Evidence-Based Review of Statin Use in Patients With Nonalcoholic Fatty Liver Disease
Meredith A. Sigler et al.
CLINICAL MEDICINE INSIGHTS-GASTROENTEROLOGY (2018)
A Novel Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonist Improves Steatohepatitis and Liver Regeneration in Mice
M. Pilar Valdecantos et al.
HEPATOLOGY (2017)
A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease
Zhonge Chen et al.
LIPIDS IN HEALTH AND DISEASE (2017)
Pathology of non-alcoholic fatty liver disease
Pierre Bedossa
LIVER INTERNATIONAL (2017)
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease
Brandon J. Perumpail et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial
Tisha R. Joy et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
Sigrid Jall et al.
MOLECULAR METABOLISM (2017)
GLP-1 Elicits an Intrinsic Gut-Liver Metabolic Signal to Ameliorate Diet-Induced VLDL Overproduction and Insulin Resistance
Rituraj Khound et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)
Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study
Hiroshi Tobita et al.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2017)
Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes
Cristina B. Guzman et al.
DIABETES OBESITY & METABOLISM (2017)
GLP-1/glucagon receptor co-agonism for treatment of obesity
Miguel A. Sanchez-Garrido et al.
DIABETOLOGIA (2017)
Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial
Daisuke Ito et al.
DIABETES CARE (2017)
Effects of a Sodium-Glucose Cotransporter 2 Inhibitor in Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus: Preliminary Prospective Study Based On Serial Liver Biopsies
Norio Akuta et al.
HEPATOLOGY COMMUNICATIONS (2017)
Polyphenols and non-alcoholic fatty liver disease: impact and mechanisms
I. Rodriguez-Ramiro et al.
PROCEEDINGS OF THE NUTRITION SOCIETY (2016)
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Timothy Hardy et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 11 (2016)
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
Ele Ferrannini et al.
DIABETES (2016)
Effect of canagliflozin on liver function tests in patients with type 2 diabetes
L. A. Leiter et al.
DIABETES & METABOLISM (2016)
Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates
S. J. Henderson et al.
DIABETES OBESITY & METABOLISM (2016)
Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy
A. Dutour et al.
DIABETES OBESITY & METABOLISM (2016)
Exenatide Improves Both Hepatic and Adipose Tissue Insulin Resistance: A Dynamic Positron Emission Tomography Study
Amalia Gastaldelli et al.
HEPATOLOGY (2016)
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
Zobair M. Younossi et al.
HEPATOLOGY (2016)
Pathophysiology of Non Alcoholic Fatty Liver Disease
Salvatore Petta et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Matthew J. Armstrong et al.
JOURNAL OF HEPATOLOGY (2016)
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2016)
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
Jeffrey Cui et al.
JOURNAL OF HEPATOLOGY (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia
Malte P. Suppli et al.
MEDICAL HYPOTHESES (2016)
Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans
Nirvair S. Kelley
METABOLIC SYNDROME AND RELATED DISORDERS (2016)
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Elena Buzzetti et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions
Michael A. Nauck et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease
Mazhar Hussain et al.
PAKISTAN JOURNAL OF MEDICAL SCIENCES (2016)
Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
Feng Sun et al.
CLINICAL THERAPEUTICS (2015)
Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes
Hiroyuki Kato et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2015)
Effect of Vildagliptin on Hepatic Steatosis
Mavin Macauley et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
NAFLD: A multisystem disease
Christopher D. Byrne et al.
JOURNAL OF HEPATOLOGY (2015)
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
Caroline Bonner et al.
NATURE MEDICINE (2015)
Citrus limonin glucoside supplementation decreased biomarkers of liver disease and inflammation in overweight human adults
Darshan S. Kelley et al.
JOURNAL OF FUNCTIONAL FOODS (2015)
Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)
Yuichiro Eguchi et al.
HEPATOLOGY RESEARCH (2015)
Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes
Ning Shao et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2014)
Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis
Thomas Klein et al.
MEDICAL MOLECULAR MORPHOLOGY (2014)
Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation
Xing-Chun Wang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes
Lise L. Gluud et al.
BMJ OPEN (2014)
Biomarkers in nonalcoholic fatty liver disease
Manuela G. Neuman et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2014)
Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging
Jessica K. Dyson et al.
FRONTLINE GASTROENTEROLOGY (2014)
Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
Jonathan E. Campbell et al.
CELL METABOLISM (2013)
Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial
K. Hermansen et al.
DIABETES OBESITY & METABOLISM (2013)
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
T. A. Wadden et al.
INTERNATIONAL JOURNAL OF OBESITY (2013)
Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease
Melania Gaggini et al.
NUTRIENTS (2013)
Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Yan Li et al.
BIOMEDICAL REPORTS (2013)
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Naga Chalasani et al.
HEPATOLOGY (2012)
GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
Jinmi Lee et al.
DIABETES & METABOLISM JOURNAL (2012)
Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice
Jun Shirakawa et al.
DIABETES (2011)
GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy
Shvetank Sharma et al.
PLOS ONE (2011)
L-carnitine ameliorated fatty liver in high-calorie diet/STZ-induced type 2 diabetic mice by improving mitochondrial function
Yunqiu Xia et al.
DIABETOLOGY & METABOLIC SYNDROME (2011)
Pioglitazone in the treatment of NASH: the role of adiponectin
A. Gastaldelli et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Exenatide in the Treatment of Diabetic Patients With Non-Alcoholic Steatohepatitis: A Case Series
Patrick R. Kenny et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Histological Course of Nonalcoholic Fatty Liver Disease in Japanese Patients - Tight glycemic control, rather than weight reduction, ameliorates liver fibrosis
Erika Hamaguchi et al.
DIABETES CARE (2010)
Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes
Safina Ali et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2009)
Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver
Dan Zheng et al.
DIABETES (2009)
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Jonathan W. Day et al.
NATURE CHEMICAL BIOLOGY (2009)
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
David C. Klonoff et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis
Young-Sun Lee et al.
DIABETES (2007)
Share Paper
